Agios Pharmaceuticals, Inc. partnered with Alnylam Pharmaceuticals, Inc. announced to develop and commercialize Alnylam's innovative preclinical siRNA targeting TMPRSS6, for patients with polycythemia vera (PV), a rare hematologic condition. Furthermore, the company aims to provide a simple, disease-modifying therapy option that targets the underlying pathophysiology of PV and to provide a breakthrough therapy option for this patient community with significant unmet needs.
Novartis received approval from the US Food and Drug Administration (FDA) for Leqvio (inclisiran) a small interfering RNA (siRNA) therapy a new strategy to lower low-density lipoprotein cholesterol also known as bad cholesterol in the bloodstream by increasing the liver's natural ability to suppress the creation of a protein that contributes to high circulating cholesterol levels to assist those who have difficulty sticking to self-administered medications with higher dose frequency.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5297
Published Date: Oct 09, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising cases of cancer across the globe and the growing partnerships and collaborations are the major factors driving the growth of the market.
The market size of small interfering RNA is anticipated to attain a CAGR of 18.5% over the forecast period, i.e., 2024-2036.
The major players in the market are Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, AInylam Pharmaceuticals, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health
The liposome based systemic therapy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.